[
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This indicates that in the near future, pro-inflammatory allogeneic dendritic cells can be extracted from healthy blood donors and later deep-frozen to be used in patients as immune enhancers.Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These cells also modify their metabolism to high OXPHOS and become less glycolytic. (B) Timeline progress related to the implications of various immunotherapies in treating brain metastasis.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "BrM formation is a complex process involving numerous signaling pathways and multiple steps, thus we have limited our focus to the main mechanism of BrM common amongst primary tumors including melanoma, breast, lung, colon, and kidney cancers (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Myeloid-derived suppressor cells (MDSCs) are alerted to the inflammation and necrosis present in the TME and work to downregulate the antitumor immune response (Fig. 2A) [29].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SRS in combination with immunotherapy has shown better clinical outcomes versus SRS or IT alone (Fig. 3) [8–10, 38, 50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This case is unique because the central nervous system (CNS) is considered as immune privileged, with limited regular immune responses observed (Fig. 2A-B) [111].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Brain microenvironment in the modulation of immunotherapy response in primary brain neoplasm versus brain metastases\nRecent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Recent research on the BrM-induced tumor microenvironment interrogation revealed a distinct population of immune cells, including infiltrating macrophages, tissue-resident microglia, T-cells, and neutrophils (Fig. 2A) [194–196].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is widely accepted that the tumor cells’ aberrant metabolic requirements lead to a nutrient scavenged microenvironment, which eventually challenges the activation and proper functioning of immune cells (Fig. 4) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The availability of immune cells surrounding BrM allows for anti-tumor activity, but the struggle for nutrients with metabolically enhanced tumor cells sheds misfortune on immune cell metabolism for their anti-tumor activity (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In contrast, metabolites such as lactate and kynurenine promote Treg or exhaustion of effector T cells, thus building an immunosuppressive TME (Fig. 4A) [257, 258].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  }
]